Scarica l'app Stockscreener
7.6904
4.48%
0.3004
Precedente Chiudi:
$7.39
Aprire:
$7.5
Volume 24 ore:
339.77K
Relative Volume:
0.15
Capitalizzazione di mercato:
$462.14M
Reddito:
$216.11M
Utile/perdita netta:
$-220.47M
Rapporto P/E:
-2.0583
EPS:
-3.7363
Flusso di cassa netto:
$-110.44M
1 W Prestazione:
+9.52%
1M Prestazione:
+10.78%
6M Prestazione:
+75.08%
1 anno Prestazione:
+76.69%
Intervallo 1D:
$7.48
$7.735
Intervallo di 1 settimana:
$6.975
$7.735
Portata 52W:
$3.8092
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Nome
Vanda Pharmaceuticals Inc
Settore
Industria
Telefono
202-734-3400
Indirizzo
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
7.685 | 444.40M | 216.11M | -220.47M | -110.44M | -3.7363 |
VRTX
Vertex Pharmaceuticals Inc
|
428.62 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
719.02 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.88 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
304.12 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.57 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-05 | Iniziato | Truist | Buy |
| 2025-11-05 | Iniziato | B. Riley Securities | Buy |
| 2024-10-31 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Downgrade | Jefferies | Buy → Hold |
| 2021-05-12 | Iniziato | BofA Securities | Buy |
| 2021-01-14 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-03-16 | Downgrade | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-07 | Downgrade | Citigroup | Buy → Neutral |
| 2019-08-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-07-25 | Downgrade | Stifel | Buy → Hold |
| 2018-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Reiterato | Jefferies | Buy |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-09-21 | Ripresa | Oppenheimer | Outperform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2017-09-14 | Reiterato | Piper Jaffray | Overweight |
| 2017-06-27 | Ripresa | Piper Jaffray | Overweight |
| 2017-05-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-04-12 | Iniziato | Oppenheimer | Outperform |
| 2016-11-09 | Iniziato | Aegis Capital | Buy |
| 2016-10-06 | Ripresa | Jefferies | Buy |
Mostra tutto
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
[EFFECT] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan
Vanda Pharmaceuticals (VNDA) Launches Nereus for Motion Sickness Relief - GuruFocus
Vanda Pharmaceuticals shares rise on Nereus commercial launch By Investing.com - Investing.com Australia
D.C.'s Vanda Pharmaceuticals launches first new prescription motion sickness drug in decades - The Business Journals
Vanda launches motion sickness drug after 40-year gap By Investing.com - Investing.com South Africa
Vanda launches motion sickness drug after 40-year gap - Investing.com
Vanda Pharmaceuticals announces U.S. commercial availability of Nereus(TM) (tradipitant), the first new pharmacologic treatment for people with motion sickness in more than 40 years - marketscreener.com
Vanda Pharmaceuticals Announces U.S. Commercial Availability Of Nereus™ (Tradipitant), The First New Pharmacologic Treatment For People With Motion Sickness In More Than 40 Years - TradingView
Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline - Investing.com
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits
Vanda Pharmaceuticals (VNDA) Launches Nereus for Motion Sickness Prevention - GuruFocus
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years - The Malaysian Reserve
Vanda Pharmaceuticals (VNDA) Launches New Motion Sickness Drug, Stock Rises - GuruFocus
NEREUS now available for online purchase as Vanda Pharmaceuticals expands access - Traders Union
MSN Money - MSN
Gastroparesis Market: Investment-Ready Growth Trends to 2034 – DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma - Barchart.com
Gastroparesis Market: Investment-Ready Growth Trends to 2034 - openPR.com
Why did Vanda Pharmaceuticals stock slide 7% pre-market today? - MSN
VNDA Stock Price, Quote & Chart | VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) - ChartMill
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 - BioSpace
Vanda Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
Vanda sets May 6 earnings release, investor call after market close - Stock Titan
BlackRock (NASDAQ: VNDA) reports 2.5M shares beneficially owned in 13G/A - Stock Titan
Vanda Pharmaceuticals (VNDA) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
VNDA Q1'26 Earnings: revenue estimate is 54.98M USD - TradingView
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence - The Malaysian Reserve
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat
Vanda Pharmaceuticals Publishes Imsidolimab Research Findings - Intellectia AI
Vanda Sues FDA Over Suspended Drug Study for Stomach Disorder - Bloomberg Law News
Vanda Pharmaceuticals announces the publication of "Efficacy and - GuruFocus
Vanda Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
The Christmas party is still ongoing in these stocks: Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals, ImmuCell - MSN
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
HC Wainwright & Co. Reiterates Vanda Pharmaceuticals (VNDA) Buy Recommendation - MSN
Vanda stock draws heavy buzz ahead of FDA verdict on Bysanti for bipolar, schizophrenia - MSN
Vanda Pharmaceuticals (VNDA) grants director 57,101 time-based RSUs - Stock Titan
Vanda Pharmaceuticals (NASDAQ: VNDA) director files initial Form 3 ownership - Stock Titan
Vanda Pharmaceuticals | DEFA14A: Others - Moomoo
Vanda Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo
[ARS] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan
Executive pay, board votes and pipeline in Vanda (NASDAQ: VNDA) 2026 proxy - Stock Titan
Vanda Pharmaceuticals adds Charles Duncan to board By Investing.com - Investing.com India
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board o - GuruFocus
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to Board of Directors to Drive Growth and Innovation in CNS Therapies 1 - Minichart
Vanda Pharmaceuticals Inc Azioni (VNDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vanda Pharmaceuticals Inc Azioni (VNDA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Moran Kevin Patrick | SVP, CFO & Treasurer |
Mar 02 '26 |
Sale |
8.27 |
42,442 |
350,821 |
411,380 |
| Wijkstrom Joakim | SVP, Chief Marketing Officer |
Mar 02 '26 |
Sale |
8.27 |
30,800 |
254,590 |
333,469 |
| Polymeropoulos Mihael Hristos | President and CEO |
Mar 02 '26 |
Sale |
8.17 |
156,235 |
1,276,971 |
2,704,496 |
| Birznieks Gunther | SVP, Business Development |
Mar 02 '26 |
Sale |
8.27 |
42,431 |
350,730 |
494,197 |
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):